Simon H Bridge

Dr. Simon H Bridge

Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2020 in Journal of Diabetes
Verified
Journal Article
Open access
PDF file
MBMargaret F. Bassendine
Margaret F. Bassendine
SBSimon H Bridge
Simon H Bridge
GMGeoff McCaughan
Geoff McCaughan
Mark GorrellMark Gorrell
Mark Gorrell
The coronavirus disease 2019 (COVID‐19) pandemic is caused by a novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), similar to SARS‐CoV and Middle East respiratory syndrome (MERS‐CoV), which cause acute respiratory distress syndrome and case fatalities. COVID‐19 disease severity is worse in older obese patients with comorbidities such as diabetes, hypertension, cardiovascular disease, and chronic lung disease. Cell binding and entry of betacoronaviruses is via their surface spike glycoprotein; SARS‐CoV binds to the metalloprotease angiotensin‐converting enzyme 2 (ACE2), MERS‐CoV utilizes dipeptidyl peptidase 4 (DPP4), and recent modeling of the structure of SARS‐CoV‐2 spike glycoprotein predicts that it can interact with human DPP4 in addition to ACE2. DPP4 is a ubiquitous membrane‐bound aminopeptidase that circulates in plasma; it is multifunctional with roles in nutrition, metabolism, and immune and endocrine systems. DPP4 activity differentially regulates glucose homeostasis and inflammation via its enzymatic activity and nonenzymatic immunomodulatory effects. The importance of DPP4 for the medical community has been highlighted by the approval of DPP4 inhibitors, or gliptins, for the treatment of type 2 diabetes mellitus. This review discusses the dysregulation of DPP4 in COVID‐19 comorbid conditions; DPP4 activity is higher in older individuals and increased plasma DPP4 is a predictor of the onset of metabolic syndrome. DPP4 upregulation may be a determinant of COVID‐19 disease severity, which creates interest regarding the use of gliptins in management of COVID‐19. Also, knowledge of the chemistry and biology of DPP4 could be utilized to develop novel therapies to block viral entry of some betacoronaviruses, potentially including SARS‐CoV‐2.

31 October 2012 in Seminars in Immunopathology
Verified
Journal Article
Closed access
PDF file
MBM. F. Bassendine
M. F. Bassendine
DSD. A. Sheridan
D. A. Sheridan
SBSimon H Bridge
Simon H Bridge
DFDaniel Felmlee
Daniel Felmlee
RNR. D. G. Neely
R. D. G. Neely

1 November 2010 in Gastroenterology
Verified
Journal Article
Closed access
DFDaniel Felmlee
Daniel Felmlee
DSDavid A. Sheridan
David A. Sheridan
SBSimon H Bridge
Simon H Bridge
SNSøren U. Nielsen
Søren U. Nielsen
RMRoss W. Milne
Ross W. Milne
MBMargaret F. Bassendine
Margaret F. Bassendine

1 September 2004 in Vaccine
Verified
Journal Article
Closed access
DPDavid Pulford
David Pulford
AGA Gates
A Gates
SBSimon H Bridge
Simon H Bridge
JRJ.H Robinson
J.H Robinson
DUD Ulaeto
D Ulaeto

1 December 2011 in Journal of Hepatology
Verified
Journal Article
Open access
MBMargaret F. Bassendine
Margaret F. Bassendine
DSDavid A. Sheridan
David A. Sheridan
DFDaniel Felmlee
Daniel Felmlee
SBSimon H Bridge
Simon H Bridge
GTGeoffrey L Toms
Geoffrey L Toms
RNR. Dermot G. Neely
R. Dermot G. Neely
Atherosclerosis has been described as a liver disease of the heart [1]. The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus–host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3]. One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to:•update the hepatologist on lipid metabolism•review the evidence that HCV exploits hepatic lipid pathways to its advantage•discuss approaches to targeting host lipid pathways as adjunctive therapy

29 October 2020 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
ANAndrew Nelson
Andrew Nelson
CSChristopher Stewart
Christopher Stewart
NKNicholas Alexander Kennedy
Nicholas Alexander Kennedy
John LodgeJohn Lodge
John Lodge
MTMark Tremelling
Mark Tremelling
CLChristopher A Lamb
Christopher A Lamb
Historical and emerging data implicate fungi in Crohn’s disease [CD] pathogenesis. However, a causal link between mycobiota, dysregulated immunity, and any impact of NOD2 variants remains elusive. This study aims to evaluate associations between NOD2 variants and faecal mycobiota in CD patients and non-CD subjects. Faecal samples were obtained from 34 CD patients [18 NOD2 mutant, 16 NOD2 wild-type] identified from the UK IBD Genetics Consortium. To avoid confounding influence of mucosal inflammation, CD patients were in clinical remission and had a faecal calprotectin <250 μg/g; 47 non-CD subjects were included as comparator groups, including 22 matched household [four NOD2 mutant] and 25 non-household subjects with known NOD2 genotype [14 NOD2 mutant] identified by the NIHR BioResource Cambridge. Faecal mycobiota composition was determined using internal transcribed spacer 1 [ITS1] sequencing and was compared with 16S rRNA gene sequences and volatile organic compounds. CD was associated with higher numbers of fungal observed taxonomic units [OTUs] [p = 0.033]. Principal coordinates analysis using Jaccard index [p = 0.018] and weighted Bray‐Curtis dissimilarities [p = 0.01] showed Candida spp. clustered closer to CD patients whereas Cryptococcus spp. clustered closer to non-CD. In CD, we found higher relative abundance of Ascomycota [p = 0.001] and lower relative abundance Basidiomycota [p = 0.019] phyla. An inverse relationship was found between bacterial and fungal Shannon diversity in NOD2 wild-type which was independent of CD [r = -0.349; p = 0.029]. This study confirms compositional changes in the gut mycobiota in CD and provides evidence that fungi may play a role in CD pathogenesis. No NOD2 genotype-specific differences were observed in the faecal mycobiota.